RESI Wraps Up in Houston and Heads Back to Boston

Life Science Investor Mandates (June 11 - June 17)

Family Office

Seeking Early Stage Oncology Opportunities

Russian Corporate VC Fund

Seeking Life Science Investments Globally

South Korean Pharmaceutical Company

Seeking to In-License Clinical Stage Therapeutics in Neurology, Hepatology, and Gastroenterology

Southwest Based VC

Seeking Pre-clinical Stage Life Science Opportunities throughout US

In This Issue

RESI Wraps Up in Houston and Heads Back to Boston

Refining the Global Target List: How to Prioritize Investor Leads

LSN Summer Reading Series Issue #4

LSN Videos

RESI 4 Recap Video, San Francisco, 2015

RESI 4 Investor Panel Videos

Investor Database

Company Database

RESI Wraps Up in Houston and Heads Back to Boston

By Scott Parks, Director of Marketing, LSN

June 8th was the 5th Redefining Early Stage Investments (RESI) conference, and the first at Houston's Texas Medical Center's Innovation Portal (TMCx). With nearly 500 registrations the 100,000 square-foot accelerator space was filled with CEOs, scientists, entrepreneurs and more than 150 investors (from LSN's 10 investor categories including: Family Offices, Hedge Funds, Venture and Private Equity). The venue served as an exhibition space as well as a partnering forum for investors and entrepreneurs who compressed a total of 700 meetings into a single day in order to network, build relationships and close investment rounds.

LSN's CEO Dennis Ford comments, "It can be overwhelming and we absolutely love that aspect. We want to give everyone who comes here more opportunities than they can make a decision about, because if we're doing that, we're doing our job. We really want to inundate everyone, for one day, and submerge them in this early stage investor world to let them get a lot of bang for their buck instead of stretching it out over a period of several days. We want to give them as much value as possible...

Refining the Global Target List: How to Prioritize Investor Leads

By Lucy Parkinson, Senior Research Manager, LSN

While creating a target list of investor contacts is a good first step on your road to financing, lists have to be used strategically. It's important to refine and prioritize your investor targets before embarking on a fundraising campaign, and in this article, I'll explain how we conduct this process at LSN.

LSN's primary goal is to help life science companies connect with investors who are a suitable fit for their opportunities. By searching the LSN Investor Platform, a fundraising executive can create a Global Target List (GTL) of potential investors in their company. This list typically includes 250 to 500 possible investors-enough to create a considerable amount of outreach work. So how can the list be filtered so this work can be conducted most effectively...

LSN Summer Reading Series Issue #4

By Michael Quigley, Director of Research, LSN

This week in the summer reading series, we explore the current categories of early stage life science investors. As a result of the significant changes the investor landscape has undergone in the past few years, many traditional players have moved downstream to later stage investments or out of the space entirely, and new faces have stepped in to fill the void. Understanding what motivates these different groups and how they operate is crucial when looking for a successful financial partnership.

Chapter 4 of The Life Science Executive's Fundraising Manifesto "Categories of Life Science Investors" explains how and why the funding landscape has changed, the types of investors who are currently funding companies, and, in general, the approach these entities take toward investing. We hope this text proves to be informative. Next week we will turn the focus inward with Chapter 5: "Knowing Who and What You Are, and Where You Fit."

Click here to download/print the PDF.

www.lifesciencenation.com

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668

Email: [email protected]